Mouse Models of Human Mature B-Cell and Plasma Cell Neoplasms

  • Siegfried Janz
  • Herbert C. MorseIII
  • Michael A. Teitell


Developing mouse models that accurately reflect features of human B-cell lineage neoplasms has been a daunting but increasingly rewarding task. Studies of spontaneous tumors or those induced by chemicals, irradiation, or retroviruses performed before the 1980s provided remarkable insights into mechanisms and genetics of lymphomagenesis. With the advent of genetic engineering, it became possible to rapidly develop and explore new models and to enhance the value of established systems. Here, we will review past and present accomplishments in modeling mature human B-cell lymphomas and plasmas cell neoplasms (PCN) in mice, examine their strengths and limitations, and discuss obstacles that must be addressed in future work. These systems have accelerated our ability to understand the development of complex disease in vivo and to develop novel therapeutic approaches to diseases, many of which are almost uniformly lethal.

The cellular origins of human mature B cell and PCN...


Multiple Myeloma Chronic Lymphocytic Leukemia Histiocytic Sarcoma Splenic Marginal Zone Lymphoma Genetically Engineer Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Alizadeh, A. A., M. B. Eisen, et al. (2000). “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.” Nature 403: 503.PubMedGoogle Scholar
  2. Amin, H. M. and R. Lai(2007). “Pathobiology of ALK+ anaplastic large-cell lymphoma.” Blood 110: 2259–2267PubMedGoogle Scholar
  3. Anderson, P. N. and M. Potter (1969). “Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane).” Nature 222: 994–5.PubMedGoogle Scholar
  4. Anderson, M. S., E. S. Venanzi, et al. (2002). “Projection of an Immunological Self Shadow Within the Thymus by the Aire Protein.” Science 298(5597): 1395–1401.PubMedGoogle Scholar
  5. Aronoff, R. and C. C. Petersen (2006). “Controlled and localized genetic manipulation in the brain.” J Cell Mol Med 10(2): 333–52.PubMedGoogle Scholar
  6. Bergsagel, P. L. and W. M. Kuehl (2005). “Molecular pathogenesis and a consequent classification of multiple myeloma.” J Clin Oncol 23(26): 6333–8.PubMedGoogle Scholar
  7. Bhutani, M., A. K. Pathak, et al. (2007). “Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.” Clin Cancer Res 13(10): 3024–32.PubMedGoogle Scholar
  8. Bichi, R., S. A. Shinton, et al. (2002). “Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.” Proc Natl Acad Sci USA 99: 6955.PubMedGoogle Scholar
  9. Bodrug, S. E., B. J. Warner, et al. (1994). “Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene.” EMBO J 13(9): 2124–30.PubMedGoogle Scholar
  10. Boumsell, L., H. Coppin, et al. (1980). “An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells.” J Exp Med 152(1): 229–34.PubMedGoogle Scholar
  11. Boylan, K. L., M. A. Gosse, et al. (2007). “A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.” Cancer Res 67(9): 4069–78.PubMedGoogle Scholar
  12. Bryant, J., L. Pham, et al. (2000). “Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models.” Lab Invest 80(4): 557–73.PubMedGoogle Scholar
  13. Calin, G. A., C. Sevignani, et al. (2004). “Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.” Proc Natl Acad Sci USA 101(9): 2999–3004.PubMedGoogle Scholar
  14. Cancro, M. P. (2004). “The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation.” Immunol Rev 202(1): 237–49.PubMedGoogle Scholar
  15. Carrasco, D. R., K. Sukhdeo, et al. (2007). “The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.” Cancer Cell 11(4): 349–60.PubMedGoogle Scholar
  16. Carrasco, D. R., G. Tonon, et al. (2006). “High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.” Cancer Cell 9(4): 313–25.PubMedGoogle Scholar
  17. Cattoretti, G., L. Pasqualucci, et al. (2005). “Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.” Cancer Cell 7(5): 445–55.PubMedGoogle Scholar
  18. Chen, W., Q. Li, et al. (2006). “A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy.” Blood 108(2): 669–77.PubMedGoogle Scholar
  19. Cheung, W. C., J. S. Kim, et al. (2004). “Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.” J Clin Invest 113(12): 1763–73.PubMedGoogle Scholar
  20. Chiarle, R., J. Z. Gong, et al. (2003). “NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.” Blood 101(5): 1919–27.PubMedGoogle Scholar
  21. Chiorazzi, N. and M. Ferrarini (2003). “B cell chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor.” Annu Rev Immunol 21: 841–94.PubMedGoogle Scholar
  22. Clynes, R., J. Wax, et al. (1988). “Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus.” Proc Natl Acad Sci USA 85: 6067–71.PubMedGoogle Scholar
  23. Crespo, M., Bosch, et al. (2003). “ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.” N Engl J Med 348(18): 1764–1775.Google Scholar
  24. Czarneski, J., Y. C. Lin, et al. (2004). “Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma.” Leukemia 18(3): 597–606.PubMedGoogle Scholar
  25. Dalton, W. and K. C. Anderson (2006). “Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.” Clin Cancer Res 12(22): 6603–10.PubMedGoogle Scholar
  26. Damle, R. N., Wasil, et al. (1999). “Ig V gene mutation status and CD38 expression as novel prognostic factors in chronic lymphocytic leukemia.” Blood 94: 1837–1839.Google Scholar
  27. Dawson, D. W., J. S. Hong, et al. (2007). “Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas.” Oncogene 26(29): 4243–52.PubMedGoogle Scholar
  28. Dohner, H., S. Stilgenbauer, et al. (2000). “Genomic aberrations and survival in chronic lymphocytic leukemia.” N Engl J Med 343(26): 1910–6.PubMedGoogle Scholar
  29. Du, Z., K. Podsypanina, et al. (2006). “Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models.” Proc Natl Acad Sci USA 103(46): 17396–401.PubMedGoogle Scholar
  30. East, J. (1970). “Immunopathology and neoplasms in New Zealand Black (NZB) and SJL/J mice.” Prog Exp Tumor Res 13: 84–134.PubMedGoogle Scholar
  31. Egle, A., A. W. Harris, et al. (2004). “VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.” Blood 103(6): 2276–83.PubMedGoogle Scholar
  32. Enno, A., J. L. O'Rourke, et al. (1995). “MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma.” Am J Pathol 147(1): 217–22.PubMedGoogle Scholar
  33. Enno, A., J. L. O'Rourke, et al. (1998). “Antigen-dependent progression of mucosa-associated lymphoid tissue (MALT)-type lymphoma in the stomach. Effects of antimicrobial therapy on gastric MALT lymphoma in mice.” Am J Pathol 152(6): 1625–32.PubMedGoogle Scholar
  34. Faderl, S., Keating, et al. (2002). “Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).” Leukemia 16(6): 1045–1052.Google Scholar
  35. Fang, W., D. L. Mueller, et al. (1996). “Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene.” Immunity 4(3): 291–9.PubMedGoogle Scholar
  36. Feeney, A. J. (1990). “Lack of N regions in fetal and neonatal mouse immunoglobulin V-D-J junctional sequences.” J Exp Med 172(5): 1377–90.PubMedGoogle Scholar
  37. Ford, R. J., L. Shen, et al. (2007). “Development of a murine model for blastoid variant mantle-cell lymphoma.” Blood 109(11): 4899–906.PubMedGoogle Scholar
  38. Fredrickson, T. H., A. W. Harris (2000). Atlas of Mouse Hematopathology. Amsterdam, Harwood Academic Publishers.Google Scholar
  39. Fredrickson, T. N., K. Lennert, et al. (1999). “Splenic marginal zone lymphomas of mice.” Am J Pathol 154(3): 805–12.PubMedGoogle Scholar
  40. Fu, T. B., L. Virgilio, et al. (1994). “Characterization and localization of the TCL-1 oncogene product.” Cancer Res 54: 6297.PubMedGoogle Scholar
  41. Ge, Y., F. Zhan, et al. (2006). “Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.” Br J Haematol 133(1): 83–92.PubMedGoogle Scholar
  42. Hallek, M., Langenmayer, et al. (1999). “Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.” Blood 93(5): 1732–1737.Google Scholar
  43. Hamano, Y., S. Hirose, et al. (1998). “Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice.” Blood 92(10): 3772–9.PubMedGoogle Scholar
  44. Hanahan, D. and R. A. Weinberg (2000). “The hallmarks of cancer.” Cell 100(1): 57–70.PubMedGoogle Scholar
  45. Hardy, R. R. (2006). “B-1 B cell development.” J Immunol 177(5): 2749–54.PubMedGoogle Scholar
  46. Hartley, J. W., S. K. Chattopadhyay, et al. (2000). “Accelerated appearance of multiple B cell lymphoma types in NFS/N mice congenic for ecotropic murine leukemia viruses.” Lab Invest 80(2): 159–69.PubMedGoogle Scholar
  47. Hassler, S., C. Ramsey, et al. (2006). “Aire-deficient mice develop hematopoetic irregularities and marginal zone B-cell lymphoma.” Blood 108(6): 1941–48.PubMedGoogle Scholar
  48. Hausherr, A., R. Tavares, et al. (2007). “Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases.” Oncogene 26(34): 4987–98.PubMedGoogle Scholar
  49. Hayakawa, K., R. R. Hardy, et al. (1983). “The –Ly-1 B— cell subpopulation in normal immunodefective, and autoimmune mice.” J Exp Med 157(1): 202–18.PubMedGoogle Scholar
  50. Herve, M., K. Xu, et al. (2005). “Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity.” J Clin Invest 115(6): 1636–43.PubMedGoogle Scholar
  51. Hockenbery, D., G. Nunez, et al. (1990). “Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.” Nature 348(6299): 334–6.PubMedGoogle Scholar
  52. Hoyer, K. K., S. W. French, et al. (2002). “Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.” Proc Natl Acad Sci USA 99(22): 14392–7.PubMedGoogle Scholar
  53. Hu, Y., S. Swerdlow, et al. (2006). “Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.” Proc Natl Acad Sci USA 103(45): 16870–5.PubMedGoogle Scholar
  54. Huang, S. Y., H. F. Tien, et al. (2004). “Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.” Am J Pathol 164(2): 747–56.PubMedGoogle Scholar
  55. Jaffe, E. S., N. L. Harris, et al. (2001a). World Health Organization Classification of Tumours. Pathology and Genetics of Haematopoietic anbd Lymphoid Tissues. Lyon, IARC Press.Google Scholar
  56. Jaffe, E. S., N. L. Harris, et al. (2001b). “Burkitt lymphoma.” Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. P. a. S. Kleihues, L.H. Lyon, IARC Press: 181–4.Google Scholar
  57. Jaffe, E. S., N. L. Harris, et al. (2001c). “Diffuse large B cell lymphoma.” Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. P. a. S. Kleihues, L.H. Lyon, IARC Press: 171–4.Google Scholar
  58. Jaffe, E. S., N. L. Harris, et al. (2001d). “Mantle cell lymphoma.” Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. P. a. S. Kleihues, L.H. Lyon, IARC Press: 168–70.Google Scholar
  59. Janz, S. (2006). “Myc translocations in B cell and plasma cell neoplasms.” DNA Repair (Amst.) 5(9–10): 1213–24.Google Scholar
  60. Johnson, A. J., D. M. Lucas, et al. (2006). “Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.” Blood 108(4): 1334–8.PubMedGoogle Scholar
  61. Kantor, A. B., C. E. Merrill, et al. (1997). “An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells.” J Immunol 158(3): 1175–86.PubMedGoogle Scholar
  62. Kichina, J. V., M. Zeremski, et al. (2006). “Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas.” Oncogene 25(6): 857–66.PubMedGoogle Scholar
  63. Kim, J., S. Han, et al. (2006). “Plasma cell tumour progression in iMyc(Emicro) gene-insertion mice.” J Pathol 209(1): 44–55.PubMedGoogle Scholar
  64. Kline, M. P., S. V. Rajkumar, et al. (2007). “ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.” Leukemia 21(7): 1549–60.PubMedGoogle Scholar
  65. Kovalchuk, A. L., J. S. Kim, et al. (2002). “IL-6 transgenic mouse model for extraosseous plasmacytoma.” Proc Natl Acad Sci USA 99(3): 1509–14.PubMedGoogle Scholar
  66. Kovalchuk, A. L., T. Kishimoto, et al. (2000). “Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc.” Leukemia 14: 1127–35.PubMedGoogle Scholar
  67. Kovalchuk, A. L., C. F. Qi, et al. (2000). “Burkitt lymphoma in the mouse.” J Exp Med 192(8): 1183–90.PubMedGoogle Scholar
  68. Kress, C. K., M; Martinez-Garcia, et al. (2007). “Tritrepenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.” PLoS ONE 2: e559.PubMedGoogle Scholar
  69. Kuehl, W. M. and P. L. Bergsagel (2005). “Early genetic events provide the basis for a clinical classification of multiple myeloma.” Hematology Am Soc Hematol Educ Program : 346–52.Google Scholar
  70. Kyle, R. A., T. M. Therneau, et al. (2002). “A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance.” N Engl J Med 346(8): 564–9.PubMedGoogle Scholar
  71. Lanier, L. L., N. L. Warner, et al. (1981). “Expression of Lyt-1 antigen on certain murine B cell lymphomas.” J Exp Med 153(4): 998–1003.PubMedGoogle Scholar
  72. Li, Y. S., K. Hayakawa, et al. (1993). “The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver.” J Exp Med 178(3): 951–60.PubMedGoogle Scholar
  73. Linden, M., N. Kirchhof, et al. (2004). “Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies.” Blood 103(7): 2779–86.PubMedGoogle Scholar
  74. Linden, M., N. Kirchhof, et al. (2005). “ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.” Leuk Res 29(4): 435–44.PubMedGoogle Scholar
  75. Loffler, D., K. Brocke-Heidrich, et al. (2007). “Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer.” Blood 110: 1330–1333PubMedGoogle Scholar
  76. McDonnell, T. J. and S. J. Korsmeyer (1991). “Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).” Nature 349(6306): 254–6.PubMedGoogle Scholar
  77. Mahboudi, F. P., J. A. Phillips, et al. (1992). “Immunoglobulin gene sequence analysis of B1 (CD5+B) cell clones in a murine model of chronic lymphocytic leukemia and Richter's syndrome.” Int J Oncol 1: 459–65.PubMedGoogle Scholar
  78. Manohar, V., E. Brown, et al. (1982). “Expression of Lyt-1 by a subset of B lymphocytes.” J Immunol 129(2): 532–8.PubMedGoogle Scholar
  79. Martin, F. and J. F. Kearney (2000). “B-cell subsets and the mature preimmune repertoire. Marginal zone and B1B cells as part of a “natural immune memory”. Immunol Rev 175: 70–79.PubMedGoogle Scholar
  80. Martin, F. and J. F. Kearney (2001). “B1 cells: similarities and differences with other B cell subsets.” Cur Opin Immunol 13(2): 195–201.Google Scholar
  81. Martin, F., A. M. Oliver, et al. (2001). “Marginal zone and B1B cells unite in the early response against T-independent blood-borne particulate antigens.” Immunity 14(5): 617–29.PubMedGoogle Scholar
  82. Metzler, M., A. Forster, et al. (2006). “A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology.” Oncogene 25(22): 3093–103.PubMedGoogle Scholar
  83. Mikkers, H. and A. Berns (2003). “Retroviral insertional mutagenesis: tagging cancer pathways.” Adv Cancer Res 88: 53–99.PubMedGoogle Scholar
  84. Mitsiades, C. S., N. S. Mitsiades, et al. (2007). “Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.” J Cell Biochem 101(4): 950–68.PubMedGoogle Scholar
  85. Miyakawa, Y., Y. Ohnishi, et al. (2004). “Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.” Biochem Biophys Res Commun 313(2): 258–62.PubMedGoogle Scholar
  86. M'Kacher, R., F. Farace, et al. (2003). “Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model.” Cancer Genet Cytogenet 143(1): 32–8.PubMedGoogle Scholar
  87. Monti, S., K. J. Savage, et al. (2005). “Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.” Blood 105(5): 1851–61.PubMedGoogle Scholar
  88. Morse, H. C., 3rd, M. R. Anver, et al. (2002). “Bethesda proposals for classification of lymphoid neoplasms in mice.” Blood 100(1): 246–58.PubMedGoogle Scholar
  89. Morse, H. C., 3rd, T. McCarty, et al. (2003). “B lymphoid neoplasms of mice: characteristics of naturally occurring and engineered diseases and relationships to human disorders.” Adv Immunol 81: 97–121.PubMedGoogle Scholar
  90. Morse, H. C., 3rd, C. F. Qi, et al. (2001). “Combined histologic and molecular features reveal previously unappreciated subsets of lymphoma in AKXD recombinant inbred mice.” Leuk Res 25(8): 719–33.PubMedGoogle Scholar
  91. Mueller, A., J. O'Rourke, et al. (2003). “Distinct gene expression profiles characterize the histopathological stages of disease in Helicobacter-induced mucosa-associated lymphoid tissue lymphoma.” Proc Natl Acad Sci USA 100(3): 1292–7.PubMedGoogle Scholar
  92. Mulligan, G., C. Mitsiades, et al. (2007). “Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.” Blood 109(8): 3177–88.PubMedGoogle Scholar
  93. Narducci, M. G., E. Pescarmona, et al. (2000). “Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.” Cancer Res 60: 2095.PubMedGoogle Scholar
  94. Ohno, S., S. Migita, et al. (1984). “Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus.” J Exp Med 159: 1762–77.PubMedGoogle Scholar
  95. Okada, T. T., F; Tokushige, et al. (1991). “Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H-2-congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease.” Eur J Immunol 21: 2743–8.PubMedGoogle Scholar
  96. Park, S. S., J. S. Kim, et al. (2005). “Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.” Cancer Res 65(4): 1306–15.PubMedGoogle Scholar
  97. Park, S. S., A. L. Shaffer, et al. (2005). “Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.” Cancer Res 65(17): 7644–52.PubMedGoogle Scholar
  98. Pearse, R. N., E. M. Sordillo, et al. (2001). “Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.” Proc Natl Acad Sci USA 98(20): 11581–6.PubMedGoogle Scholar
  99. Phillips, J. A., K. Mehta, et al. (1992). “The NZB mouse as a model for chronic lymphocytic leukemia.” Cancer Res 52(2): 437–43.PubMedGoogle Scholar
  100. Pilarski, L. M., G. Hipperson, et al. (2000). “Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.” Blood 95(3): 1056–65.PubMedGoogle Scholar
  101. Planelles, L., C. E. Carvalho-Pinto, et al. (2004). “APRIL promotes B-1 cell-associated neoplasm.” Cancer Cell 6(4): 399–408.PubMedGoogle Scholar
  102. Potter, M. (2003). “Neoplastic development in plasma cells.” Immunol Rev 194: 177–95.PubMedGoogle Scholar
  103. Potter, M. and R. C. MacCardle (1964). “Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice.” J Natl Cancer Inst 33: 497.PubMedGoogle Scholar
  104. Potter, M., M. D. Sklar, et al. (1973). “Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice.” Science 182: 592–4.PubMedGoogle Scholar
  105. Potter, M. and F. Wiener (1992). “Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations.” Carcinogenesis 13: 1681–97.PubMedGoogle Scholar
  106. Radl, J. (1981). “Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia).” Am J Pathol 105(1): 91–3.PubMedGoogle Scholar
  107. Radl, J., J. W. Croese, et al. (1988). “Animal model of human disease. Multiple myeloma.” Am J Pathol 132(3): 593–7.PubMedGoogle Scholar
  108. Radl, J., C. Van Arkel, et al. (1996). “Tenfold increased incidence of spontaneous multiple myeloma in long-term immunosuppressed aging C57BL/KaLwRij mice.” Clin.Immunol.Immunopathol 79: 155–62.PubMedGoogle Scholar
  109. Rajkumar, S. V., M. Q. Lacy, et al. (2007). “Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.” Blood Rev 21: 255–265PubMedGoogle Scholar
  110. Ramsey, C., O. Winqvist, et al. (2002). “Aire deficient mice develop multiple features of APECED phenotype and show altered immune response.” Hum Mol Genet 11(4): 397–409.PubMedGoogle Scholar
  111. Ranger, A. M., J. Zha, et al. (2003). “Bad-deficient mice develop diffuse large B cell lymphoma.” Proc Natl Acad Sci USA 100(16): 9324–9.PubMedGoogle Scholar
  112. Raveche, E. S., P. Lalor, et al. (1988). “In vivo effects of hyperdiploid Ly-1+ B cells of NZB origin.” J Immunol 141(12): 4133–9.PubMedGoogle Scholar
  113. Raveche, E. S., E. Salerno, et al. (2007). “Abnormal microRNA-16locus with synteny to human 13q14 linked to CLL in NZB mice.” Blood 109(12): 5079–86.PubMedGoogle Scholar
  114. Repacholi, M. H., A. Basten, et al. (1997). “Lymphomas in E mu-Pim1 transgenic mice exposed to pulsed 900 MHZ electromagnetic fields.” Radiat Res 147(5): 631–40.PubMedGoogle Scholar
  115. Roodman, G. D. (2006). “New potential targets for treating myeloma bone disease.” Clin Cancer Res 12(20 Pt 2): 6270s–6273s.Google Scholar
  116. Rosenbaum, H., A. W. Harris, et al. (1990). “An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.” EMBO J 9: 897–905.PubMedGoogle Scholar
  117. Said, J. W., K. K. Hoyer, et al. (2001). “TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.” Lab Invest 81(4): 555–64.PubMedGoogle Scholar
  118. Sarfati, M., Chevret, et al. (1996). “Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia.” Blood 88(11): 4259–4264.Google Scholar
  119. Schelonka, R. L., J. Tanner, et al. (2007). “Categorical selection of the antibody repertoire in splenic B cells.” Eur J Immunol 37(4): 1010–21.PubMedGoogle Scholar
  120. Schneider, P. (2005). “The role of APRIL and BAFF in lymphocyte activation.” Cur Opin Immunol 17(3): 282–9.Google Scholar
  121. Schwaller, J., P. Schneider, et al. (2007). “Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness.” Blood 109(1): 331–8.PubMedGoogle Scholar
  122. Shaughnessy, J. D. and B. Barlogie (2003). “Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.” Immunol Rev 194: 140–63.PubMedGoogle Scholar
  123. Shen, R. R., D. O. Ferguson, et al. (2006). “Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.” Blood 108(6): 1991–8.PubMedGoogle Scholar
  124. Shin, M. S., T. N. Fredrickson, et al. (2004). “High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas.” Cancer Res 64(13): 4419–27.PubMedGoogle Scholar
  125. Shultz, L. D., F. Ishikawa, et al. (2007). “Humanized mice in translational biomedical research.” Nat Rev Immunol 7(2): 118–30.PubMedGoogle Scholar
  126. Silva, S., A. L. Kovalchuk, et al. (2003). “BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations.” Cancer Res 63(24): 8656–63.PubMedGoogle Scholar
  127. Smith, M. R., I. Joshi, et al. (2006). “Murine model for mantle cell lymphoma.” Leukemia 20(5): 891–3.PubMedGoogle Scholar
  128. Stall, A. M., M. C. Farinas, et al. (1988). “Ly-1 B-cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals.” Proc Natl Acad Sci USA 85: 7312.PubMedGoogle Scholar
  129. Steele-Perkins, G., W. Fang, et al. (2001). “Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily.” Genes Dev 15(17): 2250–62.PubMedGoogle Scholar
  130. Strair, R. K., W. Sheay, et al. (2002). “Adenovirus infection of primary malignant lymphoid cells.” Leuk Lymphoma 43(1): 37–49.PubMedGoogle Scholar
  131. Strasser, A., A. W. Harris, et al. (1993). “E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.” Oncogene 8(1): 1–9.PubMedGoogle Scholar
  132. Strasser, A., S. Whittingham, et al. (1991). “Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.” Proc Natl Acad Sci USA 88: 8661–5.PubMedGoogle Scholar
  133. Sutton, P., J. O'Rourke, et al. (2004). “Immunisation against Helicobacter felis infection protects against the development of gastric MALT Lymphoma.” Vaccine 22(20): 2541–6.PubMedGoogle Scholar
  134. Tassone, P., P. Neri, et al. (2005). “Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.” Clin Cancer Res 11(11): 4251–8.PubMedGoogle Scholar
  135. Teitell, M. A. (2005). “The TCL1 family of oncoproteins: co-activators of transformation.” Nat Rev Cancer 5(8): 640–8.PubMedGoogle Scholar
  136. Teitell, M., M. A. Damore, et al. (1999). “TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues.” Proc Natl Acad Sci USA 96(17): 9809–14.PubMedGoogle Scholar
  137. Thome, M. (2004). “CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.” Nat Rev Immunol 4(5): 348–59.PubMedGoogle Scholar
  138. Troppmair, J., M. Huleihel, et al. (1988). “Plasmacytoma induction by J series of v-myc recombinant retroviruses: evidence for the requirement of two (raf and myc) oncogenes for transformation.” Curr Top Microbiol Immunol 141: 110–4.PubMedGoogle Scholar
  139. Tsujimoto, Y., L. R. Finger, et al. (1984). “Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.” Science 226(4678): 1097–9.PubMedGoogle Scholar
  140. van Lohuizen, M., S. Verbeek, et al. (1989). “Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.” Cell 56(4): 673–82.PubMedGoogle Scholar
  141. Vanderkerken, K., K. Asosingh, et al. (2003). “Multiple myeloma biology: lessons from the 5TMM models.” Immunol Rev 194: 196–206.PubMedGoogle Scholar
  142. Vanderkerken, K., E. Goes, et al. (1996). “Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography.” Br J Cancer 73: 1463–5.PubMedGoogle Scholar
  143. Victor Hoffbrand, A. and T. J. Hamblin (2007). “Is “leukemia” an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia?” Leukemia Res 31(3): 273–5.Google Scholar
  144. Virgilio, L., C. Lazzeri, et al. (1998). “Deregulated expression of TCL1 causes T cell leukemia in mice.” Proc Natl Acad Sci USA 95(7): 3885–9.PubMedGoogle Scholar
  145. Virgilio, L., M. G. Narducci, et al. (1994). “Identification of the TCL1 gene involved in T-cell malignancies.” Proc Natl Acad Sci USA 91(26): 12530–4.PubMedGoogle Scholar
  146. Weissinger, E. M., H. Mischak, et al. (1991). “Induction of plasmacytomas secreting antigen-specific monoclonal antibodies with a retrovirus expressing v-abl and c-myc.” Proc Natl Acad Sci USA 88: 8735–9.PubMedGoogle Scholar
  147. Williams, M. E., S. H. Swerdlow, et al. (1993). “Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma.” Leukemia 7(2): 241–5.PubMedGoogle Scholar
  148. Williams, M. E., C. D. Westermann, et al. (1990). “Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1locus.” Blood 76(7): 1387–91.PubMedGoogle Scholar
  149. Xiangshu Wen, D. Z., Yuji Kikuchi, et al. (2004). “Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus.” Eur J Immunol 34(10): 2740–9.PubMedGoogle Scholar
  150. Yaccoby, S., B. Barlogie, et al. (1998). “Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.” Blood 92(8): 2908–13.PubMedGoogle Scholar
  151. Yaccoby, S., W. Ling, et al. (2007). “Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.” Blood 109(5): 2106–11.PubMedGoogle Scholar
  152. Yaccoby, S., R. N. Pearse, et al. (2002). “Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.” Br J Haematol 116(2): 278–90.PubMedGoogle Scholar
  153. Yaccoby, S., M. J. Wezeman, et al. (2006). “Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.” Haematologica 91(2): 192–9.PubMedGoogle Scholar
  154. Yan, X.-j., E. Albesiano, et al. (2006). “B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.” Proc Natl Acad Sci USA 103(31): 11713–8.PubMedGoogle Scholar
  155. Yata, K. and S. Yaccoby (2004). “The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.” Leukemia 18(11): 1891–7.PubMedGoogle Scholar
  156. Yoshio-Hoshino, N., Y. Adachi, et al. (2007). “Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.” Cancer Res 67(3): 871–5.PubMedGoogle Scholar
  157. Yumoto, T. Y., Y. Yoshida, et al.(1980). “Prelymphomatous and lymphomatous changes in splenomegaly of New Zealand Black mice.” Acta Pathol Japan 30(2): 171–6.Google Scholar
  158. Zanesi, N., R. Aqeilan, et al. (2006). “Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in E{micro}-TCL1 transgenic mice.” Cancer Res 66(2): 915–20.PubMedGoogle Scholar
  159. Zapata, J. M., M. Krajewska, et al. (2000). “TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies.” J Immunol 165(9): 5084–96.PubMedGoogle Scholar
  160. Zapata, J. M., M. Krajewska, et al. (2004). “TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice.” Proc Nat Acad Sci USA 101(47): 16600–5.PubMedGoogle Scholar
  161. Zhan, F., J. Hardin, et al. (2002). “Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.” Blood 99(5): 1745–57.PubMedGoogle Scholar
  162. Zhang, B., Z. Wang, et al. (2007). “NF-{kappa}B2 mutation targets TRAF1 to induce lymphomagenesis.” Blood 110(2): 743–51.PubMedGoogle Scholar
  163. Zhang, J. C., CC; Lombardi, et al. (1994). “Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutive nuclear factor lacking transcriptional repressor functions.” Oncogene 9(7): 1931–7.PubMedGoogle Scholar
  164. Zhou, P., N. B. Levy, et al. (2001). “MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes.” Blood 97(12): 3902–9.PubMedGoogle Scholar
  165. Zhu, D., C. F. Qi, et al. (2005). “Deregulated expression of the Myc cellular oncogene drives development of mouse “Burkitt-like” lymphomas from naive B cells.” Blood 105(5): 2135–7.PubMedGoogle Scholar
  166. Zojer, N., H. Ludwig, et al. (2003). “Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma.” Blood 101(10): 4137–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Siegfried Janz
    • 1
  • Herbert C. MorseIII
  • Michael A. Teitell
  1. 1.Department of Pathology, Carver College of MedicineUniversity of IowaIowa CityUSA

Personalised recommendations